Abstract Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an
indicator of aberrant glycosylation in pancreatic cancer. CA19-9 functions as a biomarker …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC), which represents
approximately 90% of all pancreatic cancers, is an extremely aggressive and lethal disease …

CA19-9 values are regularly measured in patients with pancreatic cancer. Certainly, its
potential as a biomarker has been compromised by false negative results in CA19-9 …

The symposium “New criteria of resectability for pancreatic cancer” was held during the
33nd meeting of the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery (JSHBPS) in …

Background In pancreatic cancer, methods to predict early recurrence (ER) and identify
patients at increased risk of relapse are urgently required. Purpose To develop a radiomic …

Molecularly imprinted polymers MIPs were successfully assembled around quantum dots
(QDs), for the detection of the protein biomarker CA19-9 associated to pancreatic cancer …

Background: Carbohydrate antigen (CA) 19-9 is an established perioperative prognostic
biomarker for pancreatic ductal adenocarcinoma (PDAC). However, it is unclear how CA19 …

Pancreatic cancer (PaC) shows a clear tendency to increase in the next years and therefore
represents an important health and social challenge. Currently, there is an important need to …

Pancreatic ductal adenocarcinoma (PDAC) is highly malignant. While cancers in other
organs have shown clear improvements in 5‐year survival, the 5‐year survival rate of …

Background Inflammatory factors and fasting blood glucose were verified to be associated
with the prognosis of pancreatic ductal adenocarcinoma. The goal of this study is to confirm …